# Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

> **NCT05987176** · PHASE2 · TERMINATED · sponsor: **Imperial College London** · enrollment: 1 (actual)

## Conditions studied

- Neuroendocrine Tumor G1 (NET G1)/Carcinoid
- Neuroendocrine Tumor Grade 2
- Neuroendocrine Tumors
- Liver Metastases
- Gastroenteropancreatic Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Lutathera

## Key facts

- **NCT ID:** NCT05987176
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-02
- **Primary completion:** 2025-10-21
- **Final completion:** 2025-10-21
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987176, "Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05987176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*